Treatment Results of High-dose- rate Brachytherapy and External Beam Radiation With Long-term Androgen Deprivation Therapy for Patients With Metastatic Prostate Cancer

被引：0

作者：

Suzuki, Hirotaka ^{[1
]}

Urabe, Fumihiko ^{[1
]}

Iwatani, Kosuke ^{[1
]}

Miyajima, Keiichiro ^{[1
]}

Imai, Yu ^{[1
]}

Tashiro, Kojiro ^{[1
]}

Tsuzuki, Shunsuke ^{[1
]}

Honda, Mariko ^{[1
]}

Koike, Yusuke ^{[1
]}

Aoki, Manabu ^{[2
]}

Sato, Shun ^{[3
]}

Takahashi, Hiroyuki ^{[3
]}

Miki, Kenta ^{[1
]}

Kimura, Takahiro ^{[1
]}

机构：

[1] Jikei Univ, Dept Urol, Sch Med, Tokyo, Japan

[2] Jikei Univ, Dept Radiol, Sch Med, Tokyo, Japan

[3] Jikei Univ, Dept Pathol, Sch Med, Tokyo, Japan

来源：

ANTICANCER RESEARCH | 2023年 / 43卷 / 07期

关键词：

HDR-BT; metastatic prostate cancer; radiation therapy; oncological outcome; UNITED-STATES; RECOMMENDATIONS; RADIOTHERAPY;

D O I：

10.21873/anticanres.16486

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: A recent clinical trial indicated the usefulness of local radiation therapy of the prostate in patients with low-volume metastatic prostate cancer. High-dose-rate brachytherapy (HDR-BT) is used mainly for high-risk, localized, and locally advanced cases. However, few studies exist on the efficacy of HDR-BT and external beam radiation therapy (EBRT) for metastatic prostate cancer. Patients and Methods: We conducted a retrospective analysis of 39 patients diagnosed with regional lymph node metastasis and/or a limited number of metastases who underwent HDR-BT and EBRT with long-term androgen deprivation therapy. We utilized Cox's proportional hazards models to identify predictors of oncological outcomes. Treatment outcomes, including biochemical recurrence-free survival (BCRFS), clinical progression-free survival (CPFS), and castration-resistant prostate cancer-free survival (CRPCFS), were compared according to the clinical stage. Results: The median follow-up duration was 49 months (range=23-136 months). The 5-year BCRFS, CPFS, CRPCFS, and cancer-specific survival rates were 62.2%, 67.2%, 83.2%, and 93.4%, respectively. Based on Kaplan-Meier analysis, N1M0 and N0-1M1b showed favorable outcomes compared with N1M1a. Multivariate analysis revealed that N1M1a prostate cancer was an independent risk factor for poor BCRFS, CPFS, and CRPCFS. Conclusion: HDR-BT and EBRT with androgen deprivation therapy is a feasible approach for patients with newly diagnosed regional and low-metastatic-burden prostate cancer. However, in our cohort M1a prostate cancer had significantly inferior outcomes. A well-controlled prospective study is imperative to confirm our results.

引用

页码：3135 / 3143

页数：9

共 22 条

[1] M1a prostate cancer: Results of a Dutch multidisciplinary consensus meeting [J].

Aluwini, Shafak ;

Oprea-Lager, Daniela E. ;

de Barros, Hilda ;

Mehra, Niven ;

Stoevelaar, Herman ;

Yakar, Derya ;

van Der Poel, Henk .

BJUI COMPASS, 2021, 2 (03) :159-168

[2]

[Anonymous], National Comprehensive Cancer Network guidelines

[3] ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer [J].

Armstrong, Andrew J. ;

Szmulewitz, Russell Z. ;

Petrylak, Daniel P. ;

Holzbeierlein, Jeffrey ;

Villers, Arnauld ;

Azad, Arun ;

Alcaraz, Antonio ;

Alekseev, Boris ;

Iguchi, Taro ;

Shore, Neal D. ;

Rosbrook, Brad ;

Sugg, Jennifer ;

Baron, Benoit ;

Chen, Lucy ;

Stenzl, Arnulf .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) :2974-+

[4]

Baker BR, 2015, ONCOLOGY-NY, V29, P108

[5] Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial [J].

Boeve, Liselotte M. S. ;

Hulshof, Maarten C. C. M. ;

Vis, Andre N. ;

Zwinderman, Aeilko H. ;

Twisk, Jos W. R. ;

Witjes, Wim P. J. ;

Delaere, Karl P. J. ;

van Moorselaar, R. Jeroen A. ;

Verhagen, Paul C. M. S. ;

van Andel, George .

EUROPEAN UROLOGY, 2019, 75 (03) :410-418

[6] Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer [J].

Davis, Ian D. ;

Martin, Andrew J. ;

Stockler, Martin R. ;

Begbie, Stephen ;

Chi, Kim N. ;

Chowdhury, Simon ;

Coskinas, Xanthi ;

Frydenberg, Mark ;

Hague, Wendy E. ;

Horvath, Lisa G. ;

Joshua, Anthony M. ;

Lawrence, Nicola J. ;

Marx, Gavin ;

McCaffrey, John ;

McDermott, Ray ;

McJannett, Margaret ;

North, Scott A. ;

Parnis, Francis ;

Parulekar, Wendy ;

Pook, David W. ;

Reaume, M. Neil ;

Sandhu, Shahneen K. ;

Tan, Alvin ;

Tan, T. Hsiang ;

Thomson, Alastair ;

Tu, Emily ;

Vera-Badillo, Francisco ;

Williams, Scott G. ;

Yip, Sonia ;

Zhang, Alison Y. ;

Zielinski, Robert R. ;

Sweeney, Christopher J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (02) :121-131

[7] Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer [J].

Fizazi, Karim ;

NamPhuong Tran ;

Fein, Luis ;

Matsubara, Nobuaki ;

Rodriguez-Antolin, Alfredo ;

Alekseev, Boris Y. ;

Ozguroglu, Mustafa ;

Ye, Dingwei ;

Feyerabend, Susan ;

Protheroe, Andrew ;

De Porre, Peter ;

Kheoh, Thian ;

Park, Youn C. ;

Todd, Mary B. ;

Chi, Kim N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) :352-360

[8] Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy [J].

Imai, Yu ;

Urabe, Fumihiko ;

Iwatani, Kosuke ;

Nakazono, Minoru ;

Tashiro, Kojiro ;

Honda, Mariko ;

Aoki, Manabu ;

Sato, Shun ;

Takahashi, Hiroyuki ;

Miki, Kenta ;

Kimura, Takahiro .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (05) :698-706

[9] Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy [J].

James, N. D. ;

de Bono, J. S. ;

Spears, M. R. ;

Clarke, N. W. ;

Mason, M. D. ;

Dearnaley, D. P. ;

Ritchie, A. W. S. ;

Amos, C. L. ;

Gilson, C. ;

Jones, R. J. ;

Matheson, D. ;

Miliman, R. ;

Attard, G. ;

Chowdhury, S. ;

Cross, W. R. ;

Gillessen, S. ;

Parker, C. C. ;

Russell, J. M. ;

Berthold, D. R. ;

Brawley, C. ;

Adab, F. ;

Aung, S. ;

Birtle, A. J. ;

Bowen, J. ;

Brock, S. ;

Chakraborti, P. ;

Ferguson, C. ;

Gale, J. ;

Gray, E. ;

Hingorani, M. ;

Hoskin, P. J. ;

Lester, J. F. ;

Malik, Z. I. ;

McKinna, F. ;

McPhail, N. ;

Money-Kyrle, J. ;

O'Sullivan, J. ;

Parikh, O. ;

Protheroe, A. ;

Robinson, A. ;

Srihari, N. N. ;

Thomas, C. ;

Wagstaff, J. ;

Wylie, J. ;

Zarkar, A. ;

Parmar, M. K. B. ;

Sydes, M. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) :338-351

[10] Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial [J].

James, Nicholas D. ;

Sydes, Matthew R. ;

Clarke, Noel W. ;

Mason, Malcolm D. ;

Dearnaley, David P. ;

Spears, Melissa R. ;

Ritchie, Alastair W. S. ;

Parker, Christopher C. ;

Russell, J. Martin ;

Attard, Gerhardt ;

de Bono, Johann ;

Cross, William ;

Jones, Rob J. ;

Thalmann, George ;

Amos, Claire ;

Matheson, David ;

Millman, Robin ;

Alzouebi, Mymoona ;

Beesley, Sharon ;

Birtle, Alison J. ;

Brock, Susannah ;

Cathomas, Richard ;

Chakraborti, Prabir ;

Chowdhury, Simon ;

Cook, Audrey ;

Elliott, Tony ;

Gale, Joanna ;

Gibbs, Stephanie ;

Graham, John D. ;

Hetherington, John ;

Hughes, Robert ;

Laing, Robert ;

McKinna, Fiona ;

McLaren, Duncan B. ;

O'Sullivan, Joe M. ;

Parikh, Omi ;

Peedell, Clive ;

Protheroe, Andrew ;

Robinson, Angus J. ;

Srihari, Narayanan ;

Srinivasan, Rajaguru ;

Staffurth, John ;

Sundar, Santhanam ;

Tolan, Shaun ;

Tsang, David ;

Wagstaff, John ;

Parmar, Mahesh K. B. .

LANCET, 2016, 387 (10024) :1163-1177

← 1 2 3 →